Breast cancer rates linked to drug company profits
By
Minnie Bruce Pratt
Published Dec 23, 2006 12:41 AM
The most common form of breast cancer in the U.S. dropped by 15 percent from
2002 to 2003, says a study just released by the M.D. Anderson Cancer Center in
Houston.
Researchers believe the reason for this exciting decline may be that millions
of women stopped taking hormone replacement therapy (HRT) in 2002. That year a
study from the Women’s Health Initiative warned that women taking one
type of HRT, Prempro, risked higher breast cancer rates. Until that
announcement, about a third of U.S. women over the age of 50 took
hormone-replacement drugs prescribed by their doctors.
Breast cancer rates had been climbing since 1945, and killed an estimated
40,000 U.S. women a year. Dr. Peter Ravdin, one of the study’s authors,
said the recent dramatic decline was “the largest for a single cancer in
a single year” that he knew of. (New York Times, Dec. 15)
Drug companies and doctors had pushed HRT on women for years, saying it
prevented or minimized all sorts of ailments, from heart disease and stroke to
bone loss to mental decline. Critics of HRT were ridiculed, studies undertaken
to assess the usefulness of HRT were attacked as unnecessary, and their doctors
badgered women who resisted taking HRT.
But, as Cynthia Pearson, executive director of the National Women’s
Health Network, points out: “There was never a single clinical trial that
showed that HRT prevented cardiovascular disease or stroke. This is not a story
of science moving sedately forward, carefully adding pieces to a puzzle before
making recommendations to patients. This is a story of the corruption of the
medical and scientific community. The belief that hormones are good preventive
medicine has been a triumph of marketing over science.”
(www.womenshealthnetwork.org)
Drug companies spend an average of $10,000 to $15,000 in marketing per
physician per year. They offer doctors office catering, lavish dinners and even
free cruises. It has been shown that the factor with the most influence on
doctors’ prescribing practice is visits from pharmaceutical
representatives. Drug companies fund studies and pay physicians to give talks
at conferences, and spend more than twice as much on advertising and marketing
as on research. (Family Therapy Network, March 2000 and www.gayhealth.com)
For the launch of early HRT sales, pharmaceutical companies used some of the
most insidious and powerful of these marketing techniques.
In the 1960s, the main popularizer of HRT as “supplemental
estrogen” was gynecologist Robert Wilson. In his book “Feminine
Forever,” Wilson used sexist, heterosexist and ageist reasons to make the
natural end of the reproductive process in women seem like a dreadful
fate—what he termed the “vapid cow-like state” of menopause.
He crisscrossed the U.S. promoting his ideas—and by 1975 Wyeth’s
HRT drug Premarin was the fifth-most-prescribed medicine in the U.S. (New York
Times, July 10, 2002)
After Wilson’s death in 1981, his son revealed that Wyeth Pharmaceuticals
(as Wyeth-Ayerst) had paid all of Wilson’s expenses for “Feminine
Forever” and for his so-called “research institute.”
In 2001, before HRT dangers were publicized, drug giant Wyeth earned $900
million in sales from Prempro. The next year its sales dropped 50 percent in
six months. (New York Times, July 17, 2002)
To make their millions, drug companies have continued to market HRT products in
the teeth of evidence that shows the drugs actively harm women and in fact
bring on disease and death. Solvay Pharmaceuticals has sold the HRT Estratest,
an estrogen/testosterone combination, for 25 years without ever having received
Food and Drug Administration (FDA) approval, despite the fact that the
Nurses’ Health Study shows that the drug increases breast cancer risks in
women. The National Women’s Health Network has filed a citizens’
petition with the FDA in an attempt to halt the sales. (NWHN Alerts, Aug.
28)
Lack of science, distortion and suppression of facts, marketing hype and
failure to consider the common good is “business as usual” for big
pharmaceutical companies. Their drive for profits brings additional sickness
and suffering to people all over the world.
A Dec. 17 New York Times article points out that “The drug maker Eli
Lilly has engaged in a decade-long effort to play down the health risks of
Zyprexa, its best-selling medication for schizophrenia,” and continues to
reveal severe problems of obesity and diabetes that the company’s own
published data supports. Lilly sold $4.2 billion worth of the drug worldwide in
2005.
Pharmaceutical giants like Glaxo Smith Kline have worked ferociously to block
distribution and manufacture of generic versions of their HIV/AIDS drugs. As
the AIDS epidemic accelerates in Africa, India and the Pacific Rim countries,
affecting women in particular in growing numbers, U.S. drug companies jockey to
increase their profits by retaining their drug patents.
Of the recent study linking Wyeth’s HRT drug to breast cancer, a
spokeswoman for the company said, “Clearly, more studies are
warranted.”
On the contrary, what is warranted is the removal of the profit motive from the
health care system through the establishment of a public health program in
which people’s needs are the primary criteria for all decisions. For how
this might be possible, the world can look to the magnificent health system of
socialist Cuba.
Articles copyright 1995-2012 Workers World.
Verbatim copying and distribution of this entire article is permitted in any medium without royalty provided this notice is preserved.
Workers World, 55 W. 17 St., NY, NY 10011
Email:
[email protected]
Subscribe
[email protected]
Support independent news
DONATE